{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NSCLC%2C+Non+Small+Cell+Lung+Cancer&page=6", "query": { "condition": "NSCLC, Non Small Cell Lung Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3560, "total_pages": 356, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NSCLC%2C+Non+Small+Cell+Lung+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NSCLC%2C+Non+Small+Cell+Lung+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T21:32:41.050Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05089734", "title": "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy (SG)", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 603, "start_date": "2021-11-17", "completion_date": "2027-01", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 37, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05089734" }, { "nct_id": "NCT00514293", "title": "Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bexarotene", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Raghu Nandan, M.D., Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514293" }, { "nct_id": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Gastric Cancer", "Non Small Cell Lung Cancer", "NSCLC", "Urothelial Carcinoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "APR-246 (eprenetapopt) + Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aprea Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-06-25", "completion_date": "2022-04-30", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383938" }, { "nct_id": "NCT06692738", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1160, "start_date": "2024-11-18", "completion_date": "2030-07-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 77, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Anaheim, California + 69 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06692738" }, { "nct_id": "NCT01839955", "title": "Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "quinacrine dihydrochloride - Escalation dose", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "quinacrine dihydrochloride - Extension dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Neelesh Sharma MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-09", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839955" }, { "nct_id": "NCT05845671", "title": "Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Amivantamab 1050mg", "type": "DRUG" }, { "name": "Amivantamab 1400mg", "type": "DRUG" }, { "name": "Amivantamab (to be determined)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-07-17", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 4, "location_summary": "Duarte, California • Aurora, Colorado • Ann Arbor, Michigan", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05845671" }, { "nct_id": "NCT04040244", "title": "Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pneumonitis", "Nonsmall Cell Lung Cancer Stage III" ], "interventions": [ { "name": "Exhaled Breath Collection", "type": "OTHER" }, { "name": "Blood sample", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-12-09", "completion_date": "2022-03-10", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04040244" }, { "nct_id": "NCT01026467", "title": "Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 45, "start_date": "2010-01", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 2, "location_summary": "Syracuse, New York • Winston-Salem, North Carolina", "locations": [ { "city": "Syracuse", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026467" }, { "nct_id": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Melanoma Excluding Uveal Melanoma", "Non-small Cell Lung Cancer, Squamous or Non-squamous", "Urothelial Carcinoma", "Renal Cell Carcinoma, Clear Cell", "Castration-resistant Prostate Cancer", "Ovarian Cancer, Epithelial", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XmAb®808", "type": "BIOLOGICAL" }, { "name": "Keytruda® (pembrolizumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-12-14", "completion_date": "2025-05-20", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585034" }, { "nct_id": "NCT07090499", "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Bladder Cancer", "Urothelial Carcinoma", "Advanced Non-Small Cell Lung Cancer", "Carcinoma, Non Small Cell Lung", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Esophageal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PF-08046876", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-20", "completion_date": "2029-07-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-20T21:32:41.050Z", "location_count": 21, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090499" } ] }